
Ingo Hartung/LinkedIn
Apr 30, 2025, 03:55
Ingo Hartung: ABBV-969 Dual-Targeting STEAP1 and PSMA ADC Shows Translational Promise with TOPi Payload
Ingo Hartung, Executive Director, Head of Medicinal Chemistry and Drug Design at Merck Healthcare, posted on X:
“Regina Reilly disclosing dual-targeting STEAP1/PSMA ADC ABBV-969 carrying a permeable TOPi payload.
The dual format apparently influencing (at the shown time point) internalization. In vitro/vivo data support the translational rationale for dual targeting.”
More posts featuring AACR25.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 30, 2025, 03:47
Apr 30, 2025, 03:33
Apr 30, 2025, 00:18
Apr 29, 2025, 20:38
Apr 29, 2025, 20:04